Navigation Links
Psoriasis Cure Now launches StimulateResearch.com to Ensure That Medical Research is Part of Stimulus Bill
Date:2/6/2009

KENSINGTON, Md., Feb. 6 /PRNewswire-USNewswire/ -- "Psoriasis Cure Now," a nonprofit patient advocacy organization, has launched a micro-Web site, www.StimulateResearch.com, to help everyday Americans interested in medical research be heard in the stimulus debate that has been dominated by powerful lobbyists and special interests. The Web site allows people to write their lawmakers urging them to make biomedical research a meaningful part of any stimulus bill that emerges in the coming days. The nearly $1 trillion bill sweeping through Congress could crowd out medical research funding at the National Institutes of Health (NIH) for years to come.

"This is the fastest I have seen Washington allocate $1 trillion in my quarter century following politics," said Michael Paranzino, president of Psoriasis Cure Now. "It seems to have caught the patient advocacy community flat-footed. But medical research is every bit as 'shovel ready' and 'stimulative' as Austin's proposed Frisbee golf course or the projects Chicago won't even disclose. Dollars wasted now will not cure cancer, arthritis or psoriasis tomorrow. Our Web site lets Americans concerned about curing disease make sure medical research is not neglected as the final stimulus package is hammered out in the coming week."

The House-passed stimulus bill includes a few billion for NIH (much of it to build new buildings), and the current Senate version includes $10 billion for NIH over two years. But a bipartisan group of Senators is looking to cut more than $100 billion from the current version, and the House-Senate Conference Committee is expected to make significant additional revisions, meaning the fate of medical research is highly uncertain. For the last five years, NIH funding has been stagnant, with thousands of well-designed and 'shovel ready' grant requests by scientists from all 50 states being held up by a lack of funding.

Psoriasis Cure Now takes no position on whether the stimulus bill should pass or fail; rather, it is pointing out that spending $1 trillion in lobbyist-driven spending now could mean that vital NIH research could be starved for years to come. Its www.StimulateResearch.com site is designed to give everyday Americans a chance to be part of this debate as well.

"Silence may be golden when it's time for my kids to go to bed, but silence by patient advocates is definitely not golden during this stimulus debate," Paranzino added. "The asphalt lobbyists, the honey bee lobbyists, the state politician lobbyists --- all are out in force, seeking parts of the one trillion dollars in play. It's essential that people who want cures for AIDS, MS, autism, heart disease and diabetes be heard as well. StimulateResearch.com lets us be heard."

http://www.psoriasis-cure-now.org


'/>"/>
SOURCE Psoriasis Cure Now
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
2. Gene Insights May Improve Psoriasis Care
3. Scientists unmask genetic markers associated with psoriasis
4. An Oral Agent for the Treatment of Moderate to Severe Psoriasis Would Earn a Higher Patient Share in the United States than in Europe
5. Obesity-Related Hormone Tied to Psoriasis
6. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
7. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
8. Indigo Ointment Benefits Psoriasis Patients
9. National Psoriasis Foundation Seeks 10,000 Americans to Support Psoriasis Research for World Psoriasis Day
10. National Psoriasis Foundation Releases 2008 Study Results
11. After Fits and Starts, New Hope for Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... the California Dental Association, today announced it has signed a letter of intent ... Corporation (DBC) and Northwest Dentists Insurance Company (NORDIC). , Started by dentists 36 ...
(Date:4/28/2016)... ... 28, 2016 , ... CastCoverz!, America’s #1 trusted brand for ... oldest waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! ... daily, night, weatherproof and waterproof covers for most orthopedic devices, including but not ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the organization’s most successful events, attracting medical professionals from around the globe who ... networking events. , Opening Ceremonies Sunday, April 17 included the introduction of the ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, ... childhood mortality. This is particularly true in underdeveloped parts of Africa where clean sources ... New England’s campus in Tangier, Morocco, will examine this global health issue and consider ...
(Date:4/28/2016)... ... 28, 2016 , ... Cognizin® Citicoline is one of three ... the Healthy Ageing category, Cognizin® is being considered for this prestigious honor due ... include everything from antioxidants, lipids, proteins, and botanicals. NutraIngredients will choose a winner ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/28/2016)... , April 28, 2016 ... H1 2016" is a report that provides an ... strengthen R&D pipelines by identifying new targets and ... Company Profiles discussed in this H1 2016 ... Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx ...
Breaking Medicine Technology: